Filings

ASX Filings

Date	Description
November 21, 2016	Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial
October 28, 2016	Notice of Annual General Meeting and Proxy Form
October 17, 2016	Opthea receives $2.6M R&D tax incentive
October 10, 2016	Appendix 3B
September 12, 2016	Opthea Ph1 wAMD data presented at EURETINA 2016

There are no SEC filings available.

Data provided by Kaleidoscope.